The immunosuppressive agents, cyclosporin (CsA) and tacrolimus (FK506), display cardioprotective activities. The mechanism would consist on the inhibition of the enzyme, adenosine kinase (AK), leading to an increase in adenosine (ADO) levels. ADO, inosine (INO) and nucleotide plasma levels were measured in kidney transplant recipients before and 1, 2, 4, 6 and 8 h after the administration of CsA or FK506. After CsA and FK506 administration, ADO plasma levels significantly increased, reaching a peak level after 2 h (483 ± 124 and 429 ± 96 nm, respectively), and then progressively declined. Calculated peak values (tmax) of ADO were slightly delayed with respect to those of CsA and FK506. Treatment with rapamycin did not influence the phenomenon. The dynamic profile of plasma changes of ADO, nucleotides and INO were consistent with the inhibition of the enzyme, AK. ADO increase may be clinically relevant in terms of anti-ischaemic, tissue protecting, and immunosuppressive activities as well as in terms of nephrotoxicity
Capecchi, P.L., Rechichi, S., Lazzerini, P.E., Collini, A., Guideri, F., Ruggieri, G., et al. (2005). Cyclosporin and tacrolimus increase plasma levels of adenosine in kidney transplanted patients. TRANSPLANT INTERNATIONAL, 18(3), 289-295 [10.1111/j.1432-2277.2004.00036.x].
Cyclosporin and tacrolimus increase plasma levels of adenosine in kidney transplanted patients
Capecchi, Pier Leopoldo;Rechichi, Serena;Lazzerini, Pietro Enea;Guideri, Francesca;Ruggieri, Giuliana;Carmellini, Mario;Laghi Pasini, Franco
2005-01-01
Abstract
The immunosuppressive agents, cyclosporin (CsA) and tacrolimus (FK506), display cardioprotective activities. The mechanism would consist on the inhibition of the enzyme, adenosine kinase (AK), leading to an increase in adenosine (ADO) levels. ADO, inosine (INO) and nucleotide plasma levels were measured in kidney transplant recipients before and 1, 2, 4, 6 and 8 h after the administration of CsA or FK506. After CsA and FK506 administration, ADO plasma levels significantly increased, reaching a peak level after 2 h (483 ± 124 and 429 ± 96 nm, respectively), and then progressively declined. Calculated peak values (tmax) of ADO were slightly delayed with respect to those of CsA and FK506. Treatment with rapamycin did not influence the phenomenon. The dynamic profile of plasma changes of ADO, nucleotides and INO were consistent with the inhibition of the enzyme, AK. ADO increase may be clinically relevant in terms of anti-ischaemic, tissue protecting, and immunosuppressive activities as well as in terms of nephrotoxicityFile | Dimensione | Formato | |
---|---|---|---|
38471_UPLOAD.pdf
non disponibili
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
156.88 kB
Formato
Adobe PDF
|
156.88 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/20283
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo